Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

Recruiting now · Phase 3

Conditions studied: Breast Cancer

In brief

The aim of this study is to explore the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients (ypN+or supra/subclavicular lymph node positive) after neoadjuvant chemotherapy.

Key facts

Study ID

NCT06559696

Run by

Fujian Medical University Union Hospital

People needed

722

Starts

2024-07-15

Expected to finish

2032-07-15

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Histologically confirmed invasive breast cancer
• Underwent neoadjuvant chemotherapy
• Eastern Cooperative Oncology Group Performance Status Scale 0-2
• ypN+ after neoadjuvant chemotherapy or supraclavicular/subclavicular lymph node metastasis before system therapy
• No distant metastases
• No internal mammary nodes metastases based on images before system therapy
• Willing to follow up
• Written,informed consent

You may not qualify if…

• Without neoadjuvant chemotherapy
• Distant metastases
• Simultaneous bilateral breast cancer
• Pathological confirmation or imaging consideration of lymph node metastasis in the internal mammary before system therapy
• Had simultaneous or previous secondary malignancies, except for non-malignant melanoma skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ, contralateral non-invasive breast cancer

Where it is running

• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.